Share on StockTwits

Pernix Therapeutics Holdings (NYSE:PTX) major shareholder James Edward Jr. Smith sold 30,000 shares of Pernix Therapeutics Holdings stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $4.88, for a total transaction of $146,400.00. Following the transaction, the insider now directly owns 4,412,704 shares in the company, valued at approximately $21,533,996. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

A number of analysts have recently weighed in on PTX shares. Analysts at Needham & Company LLC reiterated a “buy” rating on shares of Pernix Therapeutics Holdings in a research note on Monday, April 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $3.25.

Shares of Pernix Therapeutics Holdings (NYSE:PTX) traded down 3.78% on Tuesday, hitting $4.83. The stock had a trading volume of 191,971 shares. Pernix Therapeutics Holdings has a 1-year low of $1.68 and a 1-year high of $6.02. The stock has a 50-day moving average of $4.8 and a 200-day moving average of $3.15. The company’s market cap is $180.4 million.

Pernix Therapeutics Holdings (NYSE:PTX) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.10) by $0.05. The company had revenue of $23.90 million for the quarter, compared to the consensus estimate of $23.82 million. During the same quarter last year, the company posted ($0.05) earnings per share. Analysts expect that Pernix Therapeutics Holdings will post $0.01 EPS for the current fiscal year.

Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.